Pharmacists in Fort Sill, Oklahoma
22 Pharmacists found in Fort Sill
Brad Kander, PHARMD
Pharmacist
4301 Mow-way Road, Reynolds Army Community Hospital (attn: Mcua-qc, Ms. Pr, Fort Sill, OK 73503
580-458-2134 580-458-2314
Dr. Brian Dale Murray, PHARM. D.
Pharmacist - Pharmacotherapy
4303 Pitman & Thomas, Fort Sill, OK 73503
580-353-1131 580-355-0994
Dr. Charles Michael Gates, PHARMD
Pharmacist - Clinician (PhC)/ Clinical Pharmacy Specialist
3009 Nw Wilson St., Attn: Credentials, Fort Sill, OK 73503
580-458-2134 580-458-2314
Mr. Gary D Compton, D.PH.
Pharmacist
4301 Mow-way Road, Reynold Army Community Hospital, Fort Sill, OK 73503
580-458-2134 580-458-2314
Gerald P Vaughan, RPH
Pharmacist
4301 Mow-way Road, Reynolds Army Community Hospital, Fort Sill, OK 73503
580-458-2134 580-458-2314
Dr. Janet Denise Seratte, PHARMD
Pharmacist
4301 Nw Wilson, Fort Sill, OK 73503
580-558-2300 580-558-2445
Dr. Janet S Shelton, D.PH.
Pharmacist
4301 Mow Way Road, Reynolds Army Community Hospital, Fort Sill, OK 73503
580-458-2134 580-458-2314
Dr. Lucia M Garcia-carmona, PHARM.D.
Pharmacist - Pharmacotherapy
4300 Mow Way Rd, Fort Sill, OK 73503
580-458-2592
Ms. Marty Jeanne Bennett, DPH
Pharmacist
4301 Mow-way Road, Reynolds Army Community Hospital (attn:ms.prescott), Fort Sill, OK 73503
580-458-2134 580-458-2314
Type of Pharmacists:
Psychiatric Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing care of patients with psychiatric illness by assessing and monitoring patients, recognizing drug-induced problems, and recommending appropriate treatment plans.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Oncology Pharmacist: A licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.